Abstracts tagged "pain"

Abstract Number: 0199 • ACR Convergence 2025
Pain Phenotypes and Social Determinants of Health in Chronic Chikungunya Arthritis: A Cross-Sectional Study
Abebawork Adem¹, Alfonso Sucerquia², Jose Forero³, Juan Alzate², Larry Moreland⁴, Gary Firestein⁵, Andres Cadena⁶ and Aileen Chang⁷, ¹George Washington University, Washington, DC, DC, ²The George Washington University, Arlington, ³The George Washington University, Arlington, VA, ⁴University of Colorado, Denver, CO, ⁵University of California, San Diego, San Diego, CA, ⁶Clinica de la Costa, Barranquilla, Colombia, ⁷The George Washington University, Washington
Background/Purpose: Chronic chikungunya arthritis (CCA) is a long-term sequela of chikungunya virus infection marked by persistent pain, disability, and reduced quality of life. While nociplastic,…
Abstract Number: 2320 • ACR Convergence 2025
Sleep Disturbance in Psoriatic Arthritis: Prevalence by Minimal Disease Activity Status and Associated Clinical Factors
Lourdes Perez Chada¹, Vivi Feather², Grace Carter², Helen Early³, Emily Tsai², Jing Cui⁴, Avery LaChance⁵, Rochelle Castillo⁶, Neda shahriari², Alexis Ogdie⁷, Monika Haack², Elizabeth Klerman², Michael Weinblatt⁸, Nancy Shadick⁹, Joseph Merola¹⁰ and Chinmayi Naik³, ¹Harvard Medical School, Wayland, MA, ²Mass General Brigham, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Jamaica Plain, MA, ⁶Brigham and Women's Hospital, Brookline, MA, ⁷Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ⁸Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁹Brigham & Women's Hospital, Boston, MA, ¹⁰UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Sleep disturbance is a common and burdensome symptom in psoriatic arthritis (PsA), but its clinical determinants remain poorly understood. Using data from the Cohort…
Abstract Number: 1965 • ACR Convergence 2025
Two-Year Outcomes of Microwave Ablation for Recurrent Monoarthritis with Synovial Hypertrophy Resistant to Medical Treatment: Expanded Cohort and Long-Term Follow-Up Results
Rabia Deniz¹, Tevfik Güzelbey², İlhan Nahit Mutlu², Kübra Kalkan³, Özgür Kılıçkesmez² and Cemal Bes⁴, ¹University of Health Sciences Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey, ²University of Health Sciences Başakşehir Çam and Sakura City Hospital, Department of Radiology, Istanbul, Turkey, ³University of Health Sciences Başakşehir Çam and Sakura City Hospital, Department of Rheumatology, Istanbul, Turkey, ⁴University of Health Sciences, Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey
Background/Purpose: Recurrent monoarthritis (RM) is a significant therapeutic challenge in rheumatology, often persisting despite NSAIDs, corticosteroids (CS), DMARDs, and biologic therapies. Local interventions like intra-articular…
Abstract Number: 1435 • ACR Convergence 2025
Impact of Treatment With Upadacitinib on Non-Nociceptive Pain and Its Relevance for the Presence of Residual Symptoms in Axial Spondyloarthritis: Results from a Multicountry Observational Study
Denis Poddubnyy¹, Victoria Navarro-Compan², Neil Basu³, Mohammad Naffaa⁴, Tianming Gao⁵, Christopher Saffore⁶, Jamie Urbanik⁷, Bhumik Parikh⁸, Peter Taylor⁹ and Philip J. Mease¹⁰, ¹Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ²Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ³Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴The Azriel's Faculty of Medicine, Bar-Ilan University, Safed, Israel; The Rheumatology Unity, Galilee Medical Center, Naharyia, Israel, ⁵AbbVie, North Chicago, IL, ⁶AbbVie Inc., waukegan, IL, ⁷AbbVie, Grayslake, IL, ⁸AbbVie, Hillsborough Township, NJ, ⁹University of Oxford, Oxford, United Kingdom, ¹⁰Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, has demonstrated improvements in inflammation and nociceptive pain in late phase clinical trials of patients with axSpA.1,2,3 However,…
Abstract Number: 1237 • ACR Convergence 2025
Six Month Clinical Outcomes of a Digital Therapeutic Augmented Virtual Care Clinic for Fibromyalgia Management
Michael Rosenbluth¹, Yifei Dai¹, Dianne Shumay¹ and Andrea Chadwick², ¹Swing Therapeutics, San Francisco, CA, ²University of Kansas School of Medicine, Kansas City, KS
Background/Purpose: Guidelines for fibromyalgia treatment recommend non-pharmacologic treatment, including cognitive behavioral therapy, alongside medications [1-3]. However, patient access to multi-modal treatment is frequently limited due…
Abstract Number: 1086 • ACR Convergence 2025
Leveraging Natural Language Processing to Uncover Real-World Trends in Cannabis Use from Clinic Notes in Electronic Health Records
Titilola Falasinnu¹, Nathan Le², Yiyu Wang², Aishwarya Alagappan², Michael Weisman³, Anushka Irani⁴, Yashaar Chaichian⁵ and Selen Bozkurt⁶, ¹Stanford School of Medicine, Palo Alto, CA, ²Stanford School of Medicine, Stanford, CA, ³Cedars-Sinai Medical Center, LOS ANGELES, CA, ⁴Mayo Clinic, Jacksonville, FL, ⁵Stanford University, Stanford, CA, ⁶Emory University School of Medicine, Atlanta, GA
Background/Purpose: Pain management in autoimmune rheumatic diseases (ARDs) increasingly includes NSAIDs, physical therapy, and self-management. However, the role of cannabis in ARD symptom relief remains…
Abstract Number: 0470 • ACR Convergence 2025
Characterization of Patients With Rheumatoid Arthritis Based on Distinct Patterns of Pain Improvement Following Treatment With Filgotinib: A Post Hoc Analysis of FINCH 1
Peter Taylor¹, Yoshiya Tanaka², Louis Dron³, Katrien Van Beneden⁴, Gerd Burmester⁵ and Bruno Fautrel⁶, ¹University of Oxford, Oxford, United Kingdom, ²University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³Cytel, Toronto, Canada, ⁴Alfasigma S.p.A., Bologna, Italy, ⁵Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁶Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France
Background/Purpose: Janus kinase inhibitors have been shown to ameliorate pain as well as inflammation in patients with rheumatoid arthritis (RA). Pain response trajectories were modeled…
Abstract Number: 0149 • ACR Convergence 2025
Effect Of Osteoporosis And Opioid Use On Mortality And Unplanned Healthcare Utilization Among Patients With Rheumatoid Arthritis
Viengneesee Thao, Molly Moore Jeffery, Nafisseh Warner and Elena myasoedova, Mayo Clinic, Rochester, MN
Background/Purpose: Patients with rheumatoid arthritis (RA) have a 2-fold increase in risk for osteoporosis compared to the general population. About 30-50% of RA patients experience…
Abstract Number: 2310 • ACR Convergence 2025
Neuropeptide influence in nociception and inflammation through immune system modulation in SPA patients
ELENA GRAU GARCIA¹, SAMUEL LEAL², Jose Ivorra Cortes³, Pablo Muñoz-Martínez⁴, Laura Mas Sanchez⁵, Daniel Ramos Castro⁶, Alba Maria Torrat Noves⁷, Iago Alcantara Alvarez⁸, Belen Villanueva Manes⁹, Miguel Simeo Vinaixa⁸, Andres Perez Hurtado¹⁰ and José Andrés Román Ivorra¹¹, ¹HUP La Fe, Valencia, Comunidad Valenciana, Spain, ²Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ³Hospital Universitario La Fe, Valencia, Comunidad Valenciana, Spain, ⁴Hospital Universitario y Politécnico La Fe, Sagunto, Spain, ⁵Hospital Universitari i Politecnic La Fe, València, Spain, ⁶Hospital Universitari i Politecnic La Fe, Valencia, Spain, ⁷Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, ⁸Rheumatology Department. HUP La Fe, Valencia, Spain, ⁹Hospital La Fe, València, Spain, ¹⁰Hospital Universitario y Politècnico La Fe, València, Comunidad Valenciana, Spain, ¹¹Hospital Universitari i Politècnic La Fe, Valencia, Spain
Background/Purpose: NGFβ and CGRP are neuropeptides with a significant role in peripheral inflammation, pain modulation and immune responses. Neuropeptides regulatory mechanisms in spondyloarthritis (SpA) remain…
Abstract Number: 1886 • ACR Convergence 2025
Thirty Percent of Older Adults with Rheumatic Disease Receive High-Risk Medication
Christine Anastasiou¹, Eric Roberts², gabriela Schmajuk³ and Jinoos Yazdany⁴, ¹Stanford University, Pleasanton, CA, ²University of California, San Francisco, SF, CA, ³University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁴UCSF, San Francisco, CA
Background/Purpose: High-risk medications (HRMs) may increase the risk of adverse events such as falls and fractures, hospitalizations, hospital length of stay, and death in older…
Abstract Number: 1424 • ACR Convergence 2025
Mapping Central Nervous System Responses To Painful Stimuli In Patients With Axial Spondyloarthritis
Mohamad Bittar¹, Yvonne Lee², Atul Deodhar³, Jennifer Barton⁴ and Alexander Stevens¹, ¹Oregon Health & Science University, Portland, OR, ²Northwestern University, Chicago, IL, ³Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁴VA Portland Health Care System/OHSU, Portland, OR
Background/Purpose: Chronic pain is one of the common causes of disability in axial spondyloarthritis (axSpA). The mechanism behind this pain is not well understood, hindering…
Abstract Number: 1236 • ACR Convergence 2025
Vestibulocortical Stimulation via Caloric Irrigation in Nociplastic Disease: Therapeutic Effects on Pain, Autonomic Functioning & Quality of Life Measures
Michael Kaplan¹, Alexandra Canori², Rebecca Howard², Talia Torkian³, Rebecca Pietro¹, Gabriela Santiago-Pichardo¹, Daniel Clauw⁴, David Putrino², Yousaf Ali¹, Laura Tabacof² and Trung Ngo⁵, ¹Division of Rheumatology, Mount Sinai Hospital, New York, ²Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, ³Division of Rheumatology, Icahn School of Medicine at Mount sinai, New York, ⁴Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI, ⁵RECOVER Injury Research Centre, The University of Queensland and Surgical, Treatment & Rehabilitation Service (STARS), Queensland, Australia
Background/Purpose: Fibromyalgia (FM) and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are prototypical nociplastic disorders marked by centralized pain & fatigue, respectively. Nociplastic symptoms — such as…
Abstract Number: 1046 • ACR Convergence 2025
Cannabis Knowledge, Attitudes, and Practices Among Rheumatology Providers: Implications for Clinical Care and Education
Joanna Zeiger¹, Patti Katz², Mary-Ann Fitzcharles³, Stuart Kassan⁴, Teresa Simon⁵ and Kaleb Michaud⁶, ¹Canna Research Foundation, Boulder, CO, ²UCSF, San Rafael, CA, ³McGill University, Montreal-West, Canada, ⁴National Jewish Health, Denver, CO, ⁵Physicians Research Center, LLC, Toms River, NJ, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose: As medical cannabis becomes increasingly integrated into clinical care, healthcare providers—particularly those managing chronic rheumatologic conditions—must navigate wide-ranging levels of knowledge, attitudes, and prescribing…
Abstract Number: 0455 • ACR Convergence 2025
Assessment of Pain Outcomes in Pooled Phase 3 Trials of a Selective, Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in Patients With Active Psoriatic Arthritis
Lihi Eder¹, Philip J. Mease², Vibeke Strand³, Alexis Ogdie⁴, Atul Deodhar⁵, Rebecca Haberman⁶, April Armstrong⁷, Alice B. Gottlieb⁸, David Roberts⁹, Laurie Eliason¹⁰, Stefan Varga¹¹, Eleni Vritzali¹², Janice Li¹¹ and Laure Gossec¹³, ¹University of Toronto, Toronto, ON, Canada, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³Stanford University School of Medicine, Palo Alto CA, Portola Valley, CA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁶NYU Langone Health, New York, NY, ⁷University of California Los Angeles, Los Angeles, CA, USA, Los Angeles, CA, ⁸Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, ⁹Bristol Myers Squibb, Uxbridge, United Kingdom, ¹⁰Bristol Myers Squibb,, Princeton, NJ, ¹¹Bristol Myers Squibb, Princeton, NJ, ¹²Bristol Myers Squibb, Boudry, Switzerland, ¹³Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: Patients rate pain as one of the most important aspects of psoriatic arthritis (PsA). Pain signaling involves a series of cytokines, including those downstream…
Abstract Number: 2261 • ACR Convergence 2025
Palindromic Rheumatism and Predictors of Progression to Rheumatoid Arthritis: Experience from a Tertiary Care Center in Northern India
Sryla Punjadath¹, Venkatesh Srinivasa Pai¹, Prativa Priyadarshani Sethi¹, ritu sangwan², Abhishek Rai³ and Ravi Kant¹, ¹All India Institute of Medical Sciences, Rishikesh, Rishikesh, Uttarakhand, India, ²AIIMS ,Rishikesh, Rishikesh, Uttarakhand, India, ³AIIMS ,RISHIKESH, Bhilai, Chhattisgarh, India
Background/Purpose: Palindromic Rheumatism (PR) is recognized as a clinical syndrome of intermittent episodes of pain, swelling, and erythema in and around joints, which are severe…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].